Posterior reversible encephalopathy syndrome in malignant hypertension secondary to focal segmental glomerulosclerosis

Abdullah, Hafez Mohammad Ammar; Ullah, Waqas; Ahmad, Ejaz; Anwer, Faiz

doi:10.1136/bcr-2016-216512

Cited by 4 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is possible that other confounding variables, unrelated to ruxolitinib, like hypertension and sepsis may have led to the development of PRES in our patient. Previous case reports have shown a correlation between control of hypertension and clinical recovery of the patients diagnosed with PRES [12,13]. The persistence of hypertension even after clinical recovery favors the fact that PRES is less likely due to hypertension in this case.…”

Section: Discussionsupporting

confidence: 64%

Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient With Primary Myelofibrosis on Ruxolitinib

Kumar¹,

Nagesh²,

Sivakolundu³

et al. 2021

Cureus

View full text Add to dashboard Cite

Posterior reversible encephalopathy syndrome (PRES) is a reversible neurological syndrome characterized by headache, seizures, altered mental status, and visual abnormalities, in association with the characteristic bilateral white matter abnormalities in the posterior cerebral hemispheres. As the name suggests, it is typically reversible with clinical recovery within a few days, while the magnetic resonance imaging (MRI) abnormalities resolve much more slowly. We present a 78-year-old female with a known diagnosis of primary myelofibrosis (PMF), on ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, presenting with altered mental status. On presentation, she was hypertensive and with possible sepsis, secondary to urinary tract infection (UTI). She was intubated because of her low Glasgow Coma Scale (GCS), to secure her airways. Computed tomography (CT) of the brain did not reveal any acute ischemic changes. MRI of the brain exhibited findings suggestive of PRES. Ruxolitinib was held and the patient was treated with antihypertensives, anticonvulsants, and antibiotics. Within 24 hours of hospitalization, the patient had a complete neurological recovery, which is diagnostic of PRES. She was extubated successfully and was discharged with a resolution of her symptoms. Although several chemotherapeutic and immunosuppressant drugs are reported to be associated with PRES, the association between ruxolitinib and PRES has not been well established. Thus, case reporting is important to highlight the possible association between ruxolitinib and PRES.

show abstract

Section: Discussionsupporting

confidence: 64%

Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient With Primary Myelofibrosis on Ruxolitinib

Kumar¹,

Nagesh²,

Sivakolundu³

et al. 2021

Cureus

View full text Add to dashboard Cite

show abstract

“…The prevalence of RPLS following PSGN is not known. Only few cases have been reported with FSGS 6 . The pathophysiology of RPLS is unclear and it appears to be related to auto-regulatory failure and hypertension leading to brain hyper perfusion resulting in breakdown of the blood-brain barrier, allowing extravasation of fluid and blood products into the brain parenchyma 5 .…”

Section: Discussionmentioning

confidence: 99%

Post-streptococcal glomerulonephritis complicated with reversible posterior leukoencephalopathy syndrome

2021

View full text Add to dashboard Cite

Introduction: Reversible posterior leukoencephalopathy syndrome(RPLS) is a clinical condition with headache, altered behavior, visual symptoms and seizures. It is associated with characteristic neuroimaging which shows vasogenic edema at occipital and parietal region commonly. Post-streptococcal glomerulonephritis(PSGN) is uncommonly associated with RPLS. Case Presentation:We report a case of 15 years old boy who presented with recurrent seizure and progressive visual impairment ten days following a sore throat, subsequently diagnosed to have PSGN with MRI evidence of RPLS. He was commenced on oral phenoxymethylpenicillin and oral verapamil. Repeat MRI after six weeks showed complete resolution of previous changes. This is a rare case of RPLS associated with PSGN.

show abstract

Drugs associated with posterior reversible encephalopathy syndrome, a worldwide signal detection study

et al. 2022

View full text Add to dashboard Cite

Posterior reversible encephalopathy syndrome in malignant hypertension secondary to focal segmental glomerulosclerosis

Cited by 4 publications

References 21 publications

Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient With Primary Myelofibrosis on Ruxolitinib

Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient With Primary Myelofibrosis on Ruxolitinib

Post-streptococcal glomerulonephritis complicated with reversible posterior leukoencephalopathy syndrome

Drugs associated with posterior reversible encephalopathy syndrome, a worldwide signal detection study

Contact Info

Product

Resources

About